Evaluates treatment initiation timing and social factors affecting access in MS, implying health equity concerns.
To assess time to disease-modifying therapy (DMT) initiation and the influence of social determinants of health (SDoH) on access to high-efficacy treatment in a regional multiple sclerosis (MS) population.
No takes yet. Share an insight, caveat, or question.
Hendrix et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: